(Reuters) -German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it said on Thursday, to boost its work on new mRNA-based cancer ...

FRANKFURT (Reuters) -German biotech firm BioNTech on Monday said that second-quarter revenues more than doubled to 261 million euros ($302 million), driven by higher revenues from its COVID-19 vaccine ...

4 Reasons Pfizer Could Be a Value Play You Can't Miss BioNTech (NASDAQ:BNTX) used its virtual annual general meeting to ...

BioNTech, once celebrated for its COVID-19 vaccines, is grappling with falling demand, restructuring and the departure of its ...

Priority will be given to frontline workers and those above the age of 65 The Mishref fairground has been prepared and organised to serve as the vaccination headquarters. Around 400 employees have ...

Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to ...

Last year, the High Court ruled that one of Moderna’s patents relating to the messenger RNA (mRNA) technology, which underpinned its COVID-19 vaccine, was valid and that Pfizer and BioNTech’s ...

BioNTech (BNTX) has reached settlement agreements with the U.S. National Institutes of Health (NIH) and the University of Pennsylvania over royalties tied to its COVID-19 vaccine, resolving disputes ...

The CHMP’s recommendation will be reviewed by the European Commission (EC), which is expected to make its final decision soon. Pfizer and BioNTech have already initiated manufacturing of the ...